About Us
GreyCoat Research
About Us
GreyCoat Research is a research organization established to support the healthy life of pets.
GreyCoat Research is creating new hope in the field of feline kidney disease care through its AIM supplements.
What is AIM?
AIM stands for Apoptosis Inhibitor of Macrophage, which is a blood protein discovered by Dr. Toru Miyazaki. In the bloodstream, AIM exists at approximately 5 μg/mL and under healthy conditions. AIM is mostly inactive by binding to a type of antibody called Immunoglobulin M (IgM). AIM binds with the various waste, such as cellular debris, damaged proteins, or inflammatory molecules released by dead cells, and as a marker, it helps to clean up the waste. This AIM’s cleaning process protects from developing diseases.
However, compared to other animals, AIM in cats’ bodies are inactivated, the inability of a cat’s AIM to detach from IgM. This means that this inability undertakes waste cleanup in the kidneys, which may cause cats’ kidney diseases and chronic inflammation. By supporting AIM to be activated in cats’ bodies, Dr. Toru Protocol supports and prevents feline kidney disease by facilitating waste clean up.
The Institute for AIM Medicine
Dr. Miyazaki Toru
- Graduated from the University of Tokyo School of Medicine in 1986
- Worked as a researcher at the Louis Pasteur University of Strasbourg/IGBMC (France) from 1992
- Principal Researcher at the Basel Institute for Immunology (Switzerland) from 1995
- Associate Professor at Center for Immunology at the University of Texas Southwestern Medical Center at Dallas (USA) from 2000
- Served as a professor at the Graduate School of Medicine, University of Tokyo, from 2006 to 2022
- Working as the President and Director of the Institute for AIM Medicine (IAM)